Literature DB >> 17192485

Antecedent hindbrain glucoprivation does not impair the counterregulatory response to hypoglycemia.

Nicole M Sanders1, Gerald J Taborsky, Charles W Wilkinson, Wendi Daumen, Dianne P Figlewicz.   

Abstract

Recurrent hypoglycemia impairs hormonal counterregulatory responses (CRRs) to further bouts of hypoglycemia. The hypothalamus and hindbrain are both critical for sensing hypoglycemia and triggering CRRs. Hypothalamic glucose sensing sites are implicated in the pathogenesis of defective CRRs; however, the contribution of hindbrain glucose sensing has not been elucidated. Using a rat model, we compared the effect of antecedent glucoprivation targeting hindbrain or hypothalamic glucose sensing sites with the effect of antecedent recurrent hypoglycemia on CRR to hypoglycemia induced 24 h later. Recurrent hypoglycemia decreased sympathoadrenal (1,470 +/- 325 vs. 3,811 +/- 540 pg/ml in controls [t = 60 min], P = 0.001) and glucagon secretion (222 +/- 43 vs. 494 +/- 56 pg/ml in controls [t = 60]), P = 0.003) in response to hypoglycemia. Antecedent 5-thio-glucose (5TG) injected into the hindbrain did not impair sympathoadrenal (3,806 +/- 344 pg/ml [t = 60]) or glucagon (513 +/- 56 pg/ml [t = 60]) responses to subsequent hypoglycemia. However, antecedent 5TG delivered into the third ventricle was sufficient to blunt CRRs to hypoglycemia. These results show that hindbrain glucose sensing is not involved in the development of defective CRRs. However, neural substrates surrounding the third ventricle are particularly sensitive to glucoprivic stimulation and may contribute importantly to the development of defective CRRs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17192485      PMCID: PMC2443712          DOI: 10.2337/db06-1025

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  40 in total

1.  Convergence of pre- and postsynaptic influences on glucosensing neurons in the ventromedial hypothalamic nucleus.

Authors:  Z Song; B E Levin; J J McArdle; N Bakhos; V H Routh
Journal:  Diabetes       Date:  2001-12       Impact factor: 9.461

2.  PVN activation is suppressed by repeated hypoglycemia but not antecedent corticosterone in the rat.

Authors:  S B Evans; C W Wilkinson; K Bentson; P Gronbeck; A Zavosh; D P Figlewicz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-11       Impact factor: 3.619

3.  Immunotoxic destruction of distinct catecholamine subgroups produces selective impairment of glucoregulatory responses and neuronal activation.

Authors:  S Ritter; K Bugarith; T T Dinh
Journal:  J Comp Neurol       Date:  2001-04-02       Impact factor: 3.215

4.  Presumed apoptosis and reduced arcuate nucleus neuropeptide Y and pro-opiomelanocortin mRNA in non-coma hypoglycemia.

Authors:  N C Tkacs; A A Dunn-Meynell; B E Levin
Journal:  Diabetes       Date:  2000-05       Impact factor: 9.461

5.  Localization of hindbrain glucoreceptive sites controlling food intake and blood glucose.

Authors:  S Ritter; T T Dinh; Y Zhang
Journal:  Brain Res       Date:  2000-02-21       Impact factor: 3.252

6.  Effects of antecedent hypoglycemia, hyperinsulinemia, and excess corticosterone on hypoglycemic counterregulation.

Authors:  K Shum; K Inouye; O Chan; J Mathoo; D Bilinski; S G Matthews; M Vranic
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-09       Impact factor: 4.310

7.  Repeated 2-deoxy-D-glucose-induced glucoprivation attenuates Fos expression and glucoregulatory responses during subsequent glucoprivation.

Authors:  N M Sanders; S Ritter
Journal:  Diabetes       Date:  2000-11       Impact factor: 9.461

8.  Chronic hypoglycemia and diabetes impair counterregulation induced by localized 2-deoxy-glucose perfusion of the ventromedial hypothalamus in rats.

Authors:  M A Borg; W P Borg; W V Tamborlane; M L Brines; G I Shulman; R S Sherwin
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

9.  Hypoglycemia-associated autonomic failure in advanced type 2 diabetes.

Authors:  Scott A Segel; Deanna S Paramore; Philip E Cryer
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

10.  Brain region-dependent effects of dexamethasone on counterregulatory responses to hypoglycemia in conscious rats.

Authors:  Darleen A Sandoval; Ling Ping; Ray Anthony Neill; Bin Gong; Kristen Walsh; Stephen N Davis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-10-14       Impact factor: 3.619

View more
  6 in total

1.  Continuous hypothalamic K(ATP) activation blunts glucose counter-regulation in vivo in rats and suppresses K(ATP) conductance in vitro.

Authors:  Craig Beall; Elizabeth Haythorne; Xiaoning Fan; Qingyou Du; Sofija Jovanovic; Robert S Sherwin; Michael L J Ashford; Rory J McCrimmon
Journal:  Diabetologia       Date:  2013-06-22       Impact factor: 10.122

2.  2. Hypoglycemia Detection.

Authors:  Vanessa H Routh; Casey M Donovan; Sue Ritter
Journal:  Transl Endocrinol Metab       Date:  2012-12

3.  The medial amygdalar nucleus: a novel glucose-sensing region that modulates the counterregulatory response to hypoglycemia.

Authors:  Ligang Zhou; Nina Podolsky; Zhen Sang; Yuyan Ding; Xiaoning Fan; Qingchun Tong; Barry E Levin; Rory J McCrimmon
Journal:  Diabetes       Date:  2010-07-13       Impact factor: 9.461

4.  Hypothalamic regulation of glucose-stimulated insulin secretion.

Authors:  Owen Chan; Robert S Sherwin
Journal:  Diabetes       Date:  2012-03       Impact factor: 9.461

Review 5.  Brain-Body Control of Glucose Homeostasis-Insights From Model Organisms.

Authors:  Alastair J MacDonald; Yu Hsuan Carol Yang; Ana Miguel Cruz; Craig Beall; Kate L J Ellacott
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-31       Impact factor: 5.555

6.  Attenuated Induction of the Unfolded Protein Response in Adult Human Primary Astrocytes in Response to Recurrent Low Glucose.

Authors:  Paul G Weightman Potter; Sam J Washer; Aaron R Jeffries; Janet E Holley; Nick J Gutowski; Emma L Dempster; Craig Beall
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-26       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.